# US 2026/0216068 A1 · Uric acid liposomes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0216068 A1 - Document ID: US20260216068A1 - Status: Published application - Kind: A1 - Application number: 19/575,333 - Filed: 2026-03-23 - Published: 2026-07-30 - Earliest claimed: 2021-10-29 - Assignees: FreeOx Biotech, S.L. - Applicants: FreeOx Biotech, S.L. - Inventors: Pedro RAMOS CABRER - Web page: https://patentgrep.com/patent/US20260216068A1 ## CPC - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) - A61K 9/1277: Preparation processes; Proliposomes - A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A liposome that encapsulate uric acid wherein the liposome has a lipid bilayer and wherein the uric acid is obtained without the use of lithium or potassium ions; methods for its preparation and uses thereof. ## Claims ### Claim 1 A liposome that encapsulates uric acid, wherein said liposome has a lipid bilayer comprising double-chain phospholipids and positively charged cholesterol, and wherein said liposome is unilamellar, wherein the uric acid is obtained by preparing a solution of co-crystals of uric acid as starting material without lithium or potassium ions. ### Claim 2 (depends on 1) The liposome according to claim 1, wherein the encapsulated amount of uric acid is between 6*10−20 and 6*10−18 moles per liposome. ### Claim 3 (depends on 1) The liposome according to claim 1, wherein said liposome has a hydrodynamic diameter measured by Dynamic Light Scattering (DLS) in water at a temperature of 25° C. of between 80 and 140 nm. ### Claim 4 (depends on 1) The liposome according to claim 1, wherein said liposome has a positively charge surface and a Z potential measured by Dynamic Light Scattering (DLS) at a temperature of 25° C. greater than 0 and lower than 15 mV. ### Claim 5 (depends on 1) The liposome according to claim 1, wherein between 2.5% and 10% molar of the double-chain phospholipids are phospholipids with one or more polyethylene glycol chains that hinder the opsonization of blood liposomes attached to a polar head of said phospholipids; and between 90 and 97.5% molar of the double chain phospholipids are phospholipids with no polyethylene glycol attached to a polar head of said phospholipids. ### Claim 6 (depends on 5) The liposome of claim 5, wherein: said double chain phospholipids with one or more polyethylene glycol chains attached to a polar head are selected from 16: 0 PEG2000 PE (or 1,2 dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]), 18: 0 PEG2000 PE (or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]), 18: 0 PEG5000 PE (or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-5000]) or combinations thereof; and said double chain phospholipids without polyethylene glycol attached to a polar head are selected from DSPC (18: 0 PC or 1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (16: 0 PC or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine)), 17: 0 PC (or 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine) or combinations thereof. ### Claim 7 (depends on 1) The liposome according to claim 1, wherein said positively charged cholesterol is dimethylaminoethane-cabamoyl-cholesterol (DC-cholesterol) hydrochloride. ### Claim 8 (depends on 7) The liposome according to claim 7, comprising a molar fraction ratio between double chain phospholipids and DC-cholesterol between 0.6: 0.4 and 0.75: 0.25. ### Claim 9 A method for the manufacture of liposomes that encapsulate uric acid, comprising the steps of: a. preparing a solution of co-crystals of uric acid with L-lysine in purified water; b. adjusting the pH of the solution to a value between 7.2 and 7.4; c) forming a lipid film; d) rehydrating the lipid film formed in step c) with the uric acid solution of step b) to obtain liposomes; e) extruding the liposomes of step d) using purified water as solvent; and f) filtering the liposomes obtained in step e) using purified water as solvent, wherein steps c) to f) are carried out free of calcium ions. ### Claim 10 (depends on 1) A pharmaceutical composition comprising a liposome according to claim 1 and at least one pharmaceutically acceptable excipient. ### Claim 11 (depends on 10) A medicine comprising the pharmaceutical composition according to claim 10. ### Claim 12 (depends on 10) A method for improving and/or treating cerebrovascular disease comprising administering the pharmaceutical composition according to claim 10 to a patient in need thereof. ### Claim 13 (depends on 1) A medicine comprising the liposome according to claim 1. ### Claim 14 (depends on 1) A method for improving and/or treating cerebrovascular disease comprising administering the liposome according to claim 1 to a patient in need thereof.